AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+11.72%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+11.72%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+11.72%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+11.72%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
Log in

NASDAQ:ICLRIcon Stock Price, Forecast & News

$162.62
-2.29 (-1.39 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$162.17
Now: $162.62
$167.16
50-Day Range
$148.90
MA: $159.26
$169.74
52-Week Range
$104.28
Now: $162.62
$178.99
Volume276,981 shs
Average Volume306,442 shs
Market Capitalization$8.72 billion
P/E Ratio23.95
Dividend YieldN/A
Beta0.86
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Read More
Icon logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.81 billion
Cash Flow$8.34 per share
Book Value$30.91 per share

Profitability

Net Income$373.99 million

Miscellaneous

Employees14,650
Market Cap$8.72 billion
Next Earnings Date7/22/2020 (Estimated)
OptionableOptionable

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Icon (NASDAQ:ICLR) Frequently Asked Questions

How has Icon's stock been impacted by COVID-19 (Coronavirus)?

Icon's stock was trading at $152.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ICLR stock has increased by 6.6% and is now trading at $162.62. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Icon?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Icon.

When is Icon's next earnings date?

Icon is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Icon.

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) issued its earnings results on Wednesday, April, 22nd. The medical research company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.02. The medical research company had revenue of $715.10 million for the quarter, compared to the consensus estimate of $711.07 million. Icon had a return on equity of 24.20% and a net margin of 13.26%. Icon's revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.63 EPS. View Icon's earnings history.

What price target have analysts set for ICLR?

11 brokerages have issued 1-year target prices for Icon's shares. Their forecasts range from $135.00 to $182.00. On average, they anticipate Icon's stock price to reach $159.18 in the next twelve months. This suggests that the stock has a possible downside of 2.1%. View analysts' price targets for Icon.

Has Icon been receiving favorable news coverage?

Headlines about ICLR stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Icon earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutIcon.

Are investors shorting Icon?

Icon saw a drop in short interest in May. As of May 15th, there was short interest totaling 874,200 shares, a drop of 15.1% from the April 30th total of 1,030,000 shares. Based on an average daily trading volume, of 359,100 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.7% of the shares of the stock are sold short. View Icon's Current Options Chain.

Who are some of Icon's key competitors?

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), CVS Health (CVS), Mastercard (MA), NVIDIA (NVDA), Visa (V), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Procter & Gamble (PG).

Who are Icon's key executives?

Icon's management team includes the following people:
  • Dr. Steven A. Cutler, CEO & Director (Age 59)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 40)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

Who are Icon's major shareholders?

Icon's stock is owned by a number of institutional and retail investors. Top institutional investors include WCM Investment Management LLC (7.13%), Wellington Management Group LLP (6.68%), Clearbridge Investments LLC (5.22%), Acadian Asset Management LLC (3.96%), Comgest Global Investors S.A.S. (3.54%) and Alliancebernstein L.P. (3.53%).

Which institutional investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Wellington Management Group LLP, Massachusetts Financial Services Co. MA, Lord Abbett & CO. LLC, Janus Henderson Group PLC, Two Sigma Investments LP, Brown Capital Management LLC, and Canada Pension Plan Investment Board.

Which institutional investors are buying Icon stock?

ICLR stock was bought by a variety of institutional investors in the last quarter, including Invesco Ltd., Zurich Insurance Group Ltd FI, WCM Investment Management LLC, Comgest Global Investors S.A.S., Clearbridge Investments LLC, Grandeur Peak Global Advisors LLC, Federated Hermes Inc., and Polen Capital Management LLC.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $162.62.

How big of a company is Icon?

Icon has a market capitalization of $8.72 billion and generates $2.81 billion in revenue each year. The medical research company earns $373.99 million in net income (profit) each year or $6.88 on an earnings per share basis. Icon employs 14,650 workers across the globe.

What is Icon's official website?

The official website for Icon is www.iconplc.com.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.